Prevention and treatment of in-stent restenosis after PCI by Guanxintongluo capsule combined dual an-tiplatelet drugs
10.3969/j.issn.1008-0074.2016.06.20
- VernacularTitle:冠心通络胶囊结合双联抗血小板药物防治 PCI 术后支架内再狭窄的临床研究
- Author:
Hongbin ZHU
;
Chongquan ZHANG
;
Weining ZHANG
;
Fenglei WAMG
- Keywords:
Coronary disease;
Angioplasty,balloon,coronary;
Coronary restenosis
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2016;25(6):629-632
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study therapeutic effect of Guanxintongluo (GXTL ) capsule combined dual antiplatelet drugs on prevention and treatment of in -stent restenosis after percutaneous coronary intervention (PCI) .Methods :A total of 82 patients with coronary heart disease undergoing stent implantation treated in our hospital were select‐ed .All patients were numbered ,and they were divided into dual antiplatelet group (n=40) and combined treatment group (n=42 ,received GXTL capsule based on dual antiplatelet group ) according to odd and even number method . Therapeutic effect was compared between two groups .Results:Compared with dual antiplatelet group after treat‐ment ,there were significant rise in total effective rates of in -stent restenosis (77.5% vs .95.2% ) ,angina pectoris (80.0% vs .95.2% ) ,ECG (77.5% vs .92.9% ) and syndrome of traditional Chinese medicine (72.5% vs .90.5% ) in combined treatment group , P< 0.05 all . There were no significant difference in liver function between two groups before and after treatment , P>0.05. Conclusion:Guanxintongluo capsule combined dual antiplatelet drugs can effectively reduce incidence rate of restenosis , improve syndrome of traditional Chinese medicine ,ECG chan‐ges ,reduce pain degree of angina pectoris in patients with coronary heart disease after PCI , which is worth extending .
